Cambridge, MA, July 28, 2009 - Intelligent Medical Devices, Inc. (IMDx) announced the issuance of U.S. Patent No. 7,566,533 entitled “Clinically Intelligent Diagnostic Devices and Methods”. This patent describes multiplexed tests for determination of the cause of one or more medical symptoms in an affected individual and the effectiveness of corresponding treatments.
The patented multiplexed tests allow for multiple probes for the detection of targets, such as infectious agents, that can cause clinical symptoms, in combination with targets, such as genetic markers, that define an individual’s resistance, tolerance, intolerance or susceptibility to a therapeutic agent. These tests can be utilized to detect multiple infectious agents and genetic markers in many biological sample types, allowing for development of a wide variety of human diagnostic kits.
These tests provide physicians with a rapid and accurate clinical diagnosis and analysis of treatment option(s). In addition, this clinically intelligent design reduces costs significantly by streamlining testing procedures.
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
For more information, please contact Sarah Toomey at +1-617-871-6431 or stoomey@intelligentmdx.com